Coronavirus’ Silver Lining: Innovation In Healthcare

In healthcare, bureaucratic rules have stymied innovation, and interest groups have committed themselves to maintaining a status quo that is often inefficient and fails to deliver better health outcomes at lower total cost of care. The crisis has changed some of this. Recognition that bureaucratic rigidity is the enemy of innovation, there has been widespread media coverage of FDA’s decision to allow anti-malaria drugs to treat COVID-19 patients, a relaxing of its rules.